AR24 notes
Financials:
- FOB Exports: 63.1 cr. (vs 61.86 cr. in FY23)
- Domestic sales: 62.81 cr. (vs 28.36 cr. in FY23)
- Foreign exchange outgo: 15.72 cr. (vs 21.35 cr. in FY23)
- Issued 8,30,893 equity shares under rights issue (7.48 cr. under final call)
- Inventory writedown: 1.73 cr.
- Product sales: 124.8 cr. (vs 90.22 cr. in FY23)
- No new promoter loans received
Product basket
-
Pharmaceutical intermediates : 32+ products; 70.38 cr. (vs 53.59 cr. in FY23)
-
Human : Antipsychotic, Antidepression, Oncology, Diabetic, Diuretic
-
Veterinary : Feed Additives, Antiparasitic, Anti-Inflammator
-
-
Fine and Specialty Chemicals : 11+ products; 55.52 cr. (vs 36.64 cr. in FY23)
- Aroma & Health, Agrochem, Polymer, Electronics
Capex
- Restatements have happened affecting previous year capexes
- Fixed asset addition: 27.54 cr. (mostly in buildings + plant & machinery)
- CWIP: 16.63 cr. (vs 41.77 cr. in FY23)
- PPE: 42.91 cr. (vs 34.68 cr. in FY23); cashflow from investing statement shows 31.14 cr. of capex vs 49.14 cr. in FY23
- Invested 27.54 cr. (vs 38.6 cr. in FY23) in new infrastructure
- Investing in 2MW solar power project in Gujarat
Manufacturing facilities
-
40,000 sqm total area (vs 36,500 sqm in FY23)
-
35 (vs 25 in FY23) glass line reactors, 28 (vs 23 in FY23) stainless steel reactors
-
18 fume hoods (same in FY23)
-
10 reaction technologies (same in FY23)
-
12 reactors for pilot plant (same in FY23)
General:
-
New scale up facilities and GMP plants are key growth drives for next years
-
Their existing presence in the electronics specialty chemicals market positions them perfectly to capitalize on the government’s push for domestic semiconductor manufacturing
-
100+ customers spread over 17 countries
-
Solidifying position as a leading building block chemical manufacturer and as a CDMO, expanded research and production capabilities
-
Commissioned all new manufacturing blocks in the recently acquired plant, new manufacturing block saves upto 15% more energy
-
2 subsidiaries: Kamalam Foundation (a Section 8 Company) and SGRL USA Inc (invested 8.3 lakhs)
-
4 products with 50%+ market share
-
Employees : 139 (vs 110 in FY23)
-
Salaries of employees other than KMP increased by 26.35% (vs 17.53% in FY23) and for KMP increased by 32.31% (vs 9.55% in FY23)
-
Disputed taxes : 4.97 cr. (vs 4.17 cr. in FY23)
-
Share price : 245.5 (low), 736 (high)
-
Shareholders : 6814 (same as FY23)
-
Promoter shareholding : 69.33% (vs 69.34% in FY23)
-
Bankers : DBS, Kotak. DBS Bank loan is repayable in 66 EMIs, carries interest rate of 3.40%. Kotak loan is repayable in 66 EMIs, carries interest rate of 3month Euribor + bank spread
R&D:
- 2.54 cr. (vs 2.08 cr. in FY23)
- Established a cutting-edge Research Center and a dedicated Pilot Plant
- Technologies: Liquid-Gas Reaction (new), High-Pressure Reaction, Cryogenic Reaction, Photo-Catalytic Reaction (new), Thin-film Distillation (new), High Fraction Distillation (new)
- Chemistries: Chlorination using HCL or Chlorine Gas, Photo-Chlorination & Bromination, Reduction using Hydride (new), DIBAL and H2 Gas (new), Friedel Crafts & Grignard, Sonagashira and Suzuki Coupling (new), Chiral Resolution
Disclosure: Invested (no transactions in last-30 days)
| Subscribe To Our Free Newsletter |
